Congress: Alzheimer's Association International Conference (AAIC) 2026
Dates: July 12-15, 2026
Location: ExCeL London, UK
Theme: Building the Roadmap to 2030
Vascular contributions to cognitive impairment and dementia (VCID) represent a critical frontier in Alzheimer's disease research and represent a major focus at AAIC 2026. Growing evidence demonstrates that vascular pathology significantly modulates AD pathogenesis and that targeting the neurovascular unit offers promising therapeutic strategies[1]. This page covers key sessions on vascular dementia, cerebral small vessel disease, blood-brain barrier dysfunction, and the intersection of vascular and neurodegenerative processes.
Autopsy studies reveal that the majority of dementia cases present with mixed pathology:
This recognition has profound implications for diagnostic accuracy, treatment approaches, clinical trial design, and understanding disease progression.
Key vascular risk factors discussed at AAIC 2026 include:
| Risk Factor | Mechanism | Impact on Cognition |
|---|---|---|
| Hypertension | Small vessel damage | 2x dementia risk |
| Diabetes | Microvascular dysfunction | 1.5-2x dementia risk |
| Hyperlipidemia | Atherosclerosis | Accelerated decline |
| Smoking | Endothelial dysfunction | Direct neurotoxicity |
| Sedentary lifestyle | Reduced cerebral blood flow | Cognitive decline |
Related pages:
Cerebral small vessel disease (CSVD) encompasses several pathological processes:
Key MRI biomarkers of CSVD include white matter hyperintensities, lacunes, microbleeds, enlarged perivascular spaces, and brain atrophy.
Related pages:
The neurovascular unit comprises endothelial cells (tight junctions), pericytes, astrocyte end-feet, neuronal processes, and basement membrane.
Key mechanisms of BBB dysfunction in cognitive impairment include tight junction degradation, pericyte loss, transport disruption, and leukocyte infiltration.
Related pages:
Vascular cognitive impairment (VCI) encompasses vascular dementia (post-stroke, multi-infarct), subcortical vascular dementia (Binswanger disease), mixed dementia, and vascular mild cognitive impairment.
Related pages:
Vascular-directed therapies discussed at AAIC 2026 include antihypertensives, statins, anti-platelet agents, and ACE inhibitors.
Related pages: